Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
Abstract Background Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-03-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13048-020-00629-4 |
| _version_ | 1797971519348932608 |
|---|---|
| author | Jing Ni Rui Zhou Xianzhong Cheng Xia Xu Wenwen Guo Xiaoxiang Chen |
| author_facet | Jing Ni Rui Zhou Xianzhong Cheng Xia Xu Wenwen Guo Xiaoxiang Chen |
| author_sort | Jing Ni |
| collection | DOAJ |
| description | Abstract Background Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and safety of olaparib in recurrent ovarian cancer. Cases presentation Three patients harbored gBRCAwt with low tumor load (LTL), while two women harbored BRCAmt with high tumor load (HTL) were recruited. Two of the three LTL patients achieved partial response, and the other showed stable disease. Both HTL patients were assessed to have progressive disease in a short time. Olaparib appears to be effective and safe for LTL recurrent ovarian cancer patients even if it is gBRCAwt, while the response is poor in HTL patients. Conclusions Tumor load may be another potential marker to predict the effect of PARP inhibitors. The present head-to-head observational series provides new evidence on this issue for further research from bench to bedside in the future. |
| first_indexed | 2024-04-11T03:33:54Z |
| format | Article |
| id | doaj.art-e04a24e2f96444e98aa4154b332e8437 |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-04-11T03:33:54Z |
| publishDate | 2020-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-e04a24e2f96444e98aa4154b332e84372023-01-02T05:58:18ZengBMCJournal of Ovarian Research1757-22152020-03-011311810.1186/s13048-020-00629-4Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational seriesJing Ni0Rui Zhou1Xianzhong Cheng2Xia Xu3Wenwen Guo4Xiaoxiang Chen5Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer ResearchDepartment of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer ResearchDepartment of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer ResearchDepartment of Chemotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer ResearchDepartment of Pathology, The Second Affiliated Hospital of Nanjing Medical UniversityDepartment of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer ResearchAbstract Background Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and safety of olaparib in recurrent ovarian cancer. Cases presentation Three patients harbored gBRCAwt with low tumor load (LTL), while two women harbored BRCAmt with high tumor load (HTL) were recruited. Two of the three LTL patients achieved partial response, and the other showed stable disease. Both HTL patients were assessed to have progressive disease in a short time. Olaparib appears to be effective and safe for LTL recurrent ovarian cancer patients even if it is gBRCAwt, while the response is poor in HTL patients. Conclusions Tumor load may be another potential marker to predict the effect of PARP inhibitors. The present head-to-head observational series provides new evidence on this issue for further research from bench to bedside in the future.http://link.springer.com/article/10.1186/s13048-020-00629-4Recurrent ovarian cancerOlaparibTumor burdenPotential marker |
| spellingShingle | Jing Ni Rui Zhou Xianzhong Cheng Xia Xu Wenwen Guo Xiaoxiang Chen Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series Journal of Ovarian Research Recurrent ovarian cancer Olaparib Tumor burden Potential marker |
| title | Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series |
| title_full | Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series |
| title_fullStr | Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series |
| title_full_unstemmed | Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series |
| title_short | Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series |
| title_sort | tumor burden is a potential marker of parp inhibitor effects in ovarian cancer a head to head observational series |
| topic | Recurrent ovarian cancer Olaparib Tumor burden Potential marker |
| url | http://link.springer.com/article/10.1186/s13048-020-00629-4 |
| work_keys_str_mv | AT jingni tumorburdenisapotentialmarkerofparpinhibitoreffectsinovariancanceraheadtoheadobservationalseries AT ruizhou tumorburdenisapotentialmarkerofparpinhibitoreffectsinovariancanceraheadtoheadobservationalseries AT xianzhongcheng tumorburdenisapotentialmarkerofparpinhibitoreffectsinovariancanceraheadtoheadobservationalseries AT xiaxu tumorburdenisapotentialmarkerofparpinhibitoreffectsinovariancanceraheadtoheadobservationalseries AT wenwenguo tumorburdenisapotentialmarkerofparpinhibitoreffectsinovariancanceraheadtoheadobservationalseries AT xiaoxiangchen tumorburdenisapotentialmarkerofparpinhibitoreffectsinovariancanceraheadtoheadobservationalseries |